The Multinational Nature of Cost-Effectiveness Analyses Alongside Multinational Clinical Trials

被引:9
|
作者
Rivero-Arias, Oliver [1 ]
Gray, Alastair [1 ]
机构
[1] Univ Oxford, Dept Publ Hlth, Hlth Econ Res Ctr, Oxford OX3 7LF, England
基金
美国国家卫生研究院;
关键词
cost-effectiveness; economic evaluation; multinational randomized controlled trials; multinational studies; review; ECONOMIC EVALUATIONS; TRANSFERABILITY; PHARMACEUTICALS; COUNTRIES;
D O I
10.1111/j.1524-4733.2009.00582.x
中图分类号
F [经济];
学科分类号
02 ;
摘要
Objectives: Applied and methodological evidence to the conduct of economic evaluations alongside multinational clinical trials have appeared in the literature over the last decade. Nevertheless, little is known about the number and identity of countries participating in these studies. A structured review was carried out to assess the reporting of the multinational nature of these studies. Methods: A structured review was conducted by using online databases from January 1996 to December 2007. Articles were included if they reported cost-effectiveness analysis alongside a multinational randomized trial with individual patient-level data on resource use and outcome in more than one country. Key data extracted included country information, sample size, unit cost collection, methods to calculate costs and effects, and the reporting of incremental cost-effectiveness ratios. Results: Sixty-five studies out of a total of 591 articles identified in the original search fulfilled the inclusion criteria and were included in the review. Information about countries participating in the trial was not reported in 16 (26%) of the 65 studies. The overall sample size from all the randomized controlled trials identified was estimated to be 172,401 patients. Country-specific sample size was reported for 74,852 (43%) of the patients, but the country contribution was unknown for 97,549 (57%) of the participants. Conclusion: The reporting of the multinational nature of these studies is currently inadequate. Therefore, future guidelines of transferability of economic evaluations across settings should emphasize the importance of reporting the number and identity of countries and their contribution to the overall sample size in cost-effectiveness analyses alongside multinational clinical trials.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 50 条
  • [41] Does cost-effectiveness play a role in clinical trials?
    Steele, Tace
    Pawaskar, Manjiri
    Balkrishnan, Rajesh
    Fleischer, Alan
    Feldman, Steven R.
    DERMATOLOGIC THERAPY, 2007, 20 (02) : 110 - 119
  • [42] The Analysis of Multinational Cost-Effectiveness Data for Reimbursement DecisionsA Critical Appraisal of Recent Methodological Developments
    Andrea Manca
    Mark J. Sculpher
    Ron Goeree
    PharmacoEconomics, 2010, 28 : 1079 - 1096
  • [43] Multinational cost-effectiveness analysis of empagliflozin for heart failure patients with ejection fraction >40%
    Kolovos, Spyros
    Bellanca, Leana
    Groyer, Harinala
    Rosano, Giuseppe M. C.
    Sole, Alexandra
    Gaultney, Jennifer
    Linden, Stephan
    ESC HEART FAILURE, 2023, 10 (06): : 3385 - 3397
  • [44] Development of a method to increase power in economic analyses of multinational trials
    Friedman, J
    Weinfurt, K
    Curtis, L
    Gnanasakthy, A
    Schulman, K
    CIRCULATION, 2002, 106 (16) : E105 - E106
  • [45] Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis
    Greenberg, D
    Rosen, AB
    Olchanski, NV
    Stone, PW
    Nadai, J
    Neumann, PJ
    BMJ-BRITISH MEDICAL JOURNAL, 2004, 328 (7455): : 1536 - 1537
  • [46] Challenges of subgroup analyses in multinational clinical trials: Experiences from the MERIT-HF trial
    Wedel, H
    DeMets, D
    Deedwania, P
    Fagerberg, B
    Goldstein, S
    Gottlieb, S
    Hjalmarson, A
    Kjekshus, J
    Waagstein, F
    Wikstrand, J
    AMERICAN HEART JOURNAL, 2001, 142 (03) : 502 - 511
  • [47] OPTIMAL COST-EFFECTIVENESS ANALYSES
    NIGHTINGALE, SD
    JOURNAL OF GENERAL INTERNAL MEDICINE, 1992, 7 (03) : 369 - 370
  • [48] Interpretation of cost-effectiveness analyses
    Douglas K. Owens
    Journal of General Internal Medicine, 1998, 13 : 716 - 717
  • [49] Cost-effectiveness analyses - Reply
    Prosser, LA
    Stinnett, AA
    Goldman, L
    Weinstein, MC
    ANNALS OF INTERNAL MEDICINE, 2001, 135 (05) : 382 - 383
  • [50] A REVIEW OF COST-EFFECTIVENESS ANALYSES
    HURLEY, S
    MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 : S20 - S23